Alnylam Pharmaceuticals (ALNY) Stock Movement Summary Alnylam Pharmaceuticals experienced gains following a stock rating upgrade from Freedom Capital Markets to Buy from Hold, citing AMVUTTRA's strong revenue growth. Other firms including RBC Capital and BofA Securities also adjusted their price targets while maintaining positive ratings. In Q4 2025, ALNY reported adjusted earnings of $1.25 per share, beating the consensus estimate of $1.16. However, total revenues of $1.10 billion missed the consensus estimate of $1.14 billion. Net product revenues were $994.7 million, up 121% year-over-year, driven by increased sales of Amvuttra following label expansion for cardiomyopathy treatment, as well as sales of Givlaari and Oxlumo. The company achieved its first full year of profitability in 2025.
Read full analysisAlnylam Pharmaceuticals (ALNY) Stock Movement Summary Alnylam Pharmaceuticals experienced gains following a stock rating upgrade from Freedom Capital Markets to Buy from Hold, citing AMVUTTRA's strong revenue growth. Other firms including RBC Capital and BofA Securities also adjusted their price targets while maintaining positive ratings. In Q4 2025, ALNY reported adjusted earnings of $1.25 per share, beating the consensus estimate of $1.16. However, total revenues of $1.10 billion missed the consensus estimate of $1.14 billion. Net product revenues were $994.7 million, up 121% year-over-year, driven by increased sales of Amvuttra following label expansion for cardiomyopathy treatment, as well as sales of Givlaari and Oxlumo. The company achieved its first full year of profitability in 2025.
Alnylam Pharmaceuticals is a biotech company specializing in RNA interference (RNAi) therapeutics, with its lead drug AMVUTTRA (vutrisiran) approved for treating hereditary transthyretin-mediated amyloidosis. The company achieved its first full year of profitability in 2025, driven by AMVUTTRA's label expansion into cardiomyopathy. Today's move reflects continued investor reaction to an analyst upgrade highlighting AMVUTTRA's growth trajectory.